[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 157
Citations 0
Comment & Response
December 13, 2018

Inappropriate Grading of Adverse Events in Cancer Clinical Trials

Author Affiliations
  • 1Fudan University Shanghai Cancer Center, Shanghai, China
  • 2Rizhao City Hospital of Traditional Chinese Medicine, Rizhao, China
JAMA Oncol. 2019;5(2):269. doi:10.1001/jamaoncol.2018.5849

To the Editor Consideration of toxic effects is a critical part of cancer treatment. Therefore, the grading and reporting of all grades of adverse events, especially high-grade adverse events, must be standardized to allow for consistency and comparison across trials. The Common Terminology Criteria for Adverse Events (CTCAE) has been widely used for reporting of adverse events in oncology journals and at meetings.1